1. DDBJ/CIB Human Genomics Studio Created on Apr 28, 2000; Last modified on May 29, 2000 http://studio.nig.ac.jp/

Created on Apr 28, 2000; Last modified on May 29, 2000

2. Human Genomics Studio Move to main page Move to Japanese main page Please crick the chromosomeyou would like to see (list of ordered genomic sequences will appear). http://studio.nig.ac.jp/main.html

[Move to main page] [Move to Japanese main page] Please click the chromosome you would like to see (list of ordered genomic sequences will appear).

3. Genomics And Its Impact On Medicine And Society: 2001 Primer Serwis Katalog w Wirtualna Polska S.A. pierwszy portal w Polsce. http://www.ornl.gov/hgmis/publicat/primer2001

Genomics and Its Impact on Medicine and Society A Primer a publication of the U.S. Department of Energy Human Genome Program October 2001 Use the buttons to navigate between chapters and the button to return to this table of contents. This document is also available in printer-friendly PDF format , viewable with Adobe Acrobat. Powerpoint slides are available to accompany this Primer. Genomics 101: The Basics The Human Genome Project: A Little Bit of History Human Genome Project Goals 1998-2003 What We've Learned So Far...Achievement of a Draft Human Genome Sequence ... Dictionary of Genetic Terms Search This Report: This document may be cited in the following style: Human Genome Program, U.S. Department of Energy, Genomics and Its Impact on Medicine and Society: A 2001 Primer For printed copies, please contact Laura Yust at Oak Ridge National Laboratory. Send questions or comments to the author, Denise K. Casey

4. Gene(sis): Contemporary Art Explores Human Genomics Gene(sis) Contemporary Art Explores human genomics is a major traveling exhibitionthat showcases powerful new artwork created in direct response to recent http://www.gene-sis.net/home.html

Gene(sis): Contemporary Art Explores Human Genomics is a major traveling exhibition that showcases powerful new artwork created in direct response to recent developments in human genomics. This research is having an enormous impact on artistic practice, providing new tools, processes, materials, and issues for consideration. Organized by the Henry Art Gallery, Gene(sis) seeks to bridge art and science by elucidating technical advances for a lay audience and examining ethical issues raised by genomic research. Recognizing the complexity that these new opportunities present, curator Robin Held developed the exhibition during three years of on-going dialogue with geneticists, artists, science historians, medical ethicists, and art historians. In the spirit of fostering dialogue across disciplines, an extensive array of public programming is slated at each tour venue in conjunction with the exhibition. Gene(sis) seeks to encourage public discourse and deeper understanding of genomics and its potential impact on our everyday lives. Courtesy the artist and Max Protetch Gallery, New York

5. Gene(sis): Contemporary Art Explores Human Genomics Gene(sis) Contemporary Art Explores human genomics http://www.gene-sis.net/

6. Genome Therapeutics Corporation - Programs And Services - Human Genomics Genome Therapeutics' human genomics program identifies human genes thatare responsible for disease. We use positional cloning strategies http://www.genomecorp.com/programs/human-genomics.shtml

Product Pipeline Ramoplanin Infectious Disease Human Genomics ... Sequence Data Genome Therapeutics has a tradition of excellence in human genome mapping and analysis, as the Company was the first organization to publish a primary genetic linkage map of the entire human genome in 1987, and is the only commercial participant in the Human Genome Project. The Company’s top-tier human genomics programs incorporate unique resources and innovative technologies to elucidate the root causes of carefully chosen human diseases with unmet medical needs in the hopes of identifying new targets for drug development. In December 1996, Genome Therapeutics announced its first human genomics alliance – a deal now worth a potential $81 million – to develop novel treatments for asthma with Schering-Plough, a world leader in respiratory care products. Utilizing core capabilities in population genetics, bioinformatics and genomic sequencing, Genome Therapeutics has identified two genes associated with asthma susceptibility, published the results of the discovery in Nature and the drug discovery program has advanced into the high-throughput screening phase.

7. Genome Therapeutics Corporation - Programs And Services Innovative human genomics programs and new initiatives in Functional Genomics andPharmacogenomics complement the Company's established Pathogen programs. http://www.genomecorp.com/programs/index.shtml

Product Pipeline Ramoplanin Infectious Disease Human Genomics ... Sequence Data Genome Therapeutics has created a balanced platform that will enable it to continue to develop into a fully-integrated genomics and drug discovery company. Innovative human genomics programs and new initiatives in Functional Genomics and Pharmacogenomics complement the Company's established Pathogen programs. Our first product, Ramoplanin , is in Phase III clinical trials in the United States for the suppression of vancomycin-resistant enterococci (VRE) in the gastrointestinal tract and the prevention of bloodstream infections caused by VRE. Our Infectious Disease Program focuses on identifying the DNA sequence of medically important bacteria and fungi. Genome Therapeutics believes that the development of novel antibiotics and vaccines based on new pathogen targets identified using genomic information may be less prone to the rapid development of resistance than antibiotics that are only modified versions of existing drugs. Human Genomics focuses on identifying human genes that are responsible for various diseases. In some human programs, the Company uses positional cloning strategies, while in others it is employing a disease-gene modeling approach based on rare genetic disorders.

8. The Center For Human Genomics Homepage for the Center for human genomics and Section on MedicalGenetics at Wake Forest University Baptist Medical Center. http://www.wfubmc.edu/genomics/

document.write("" + day + month); document.write(myweekday + ", " + (2002) + ""); Welcome to the Center for Human Genomics Directors' welcome Research Priorities Faculty Profiles Education and Employment ... Contact us Current Highlights: Discovery of MSRI as a prostate cancer gene: Supplemental data for Am.J.Hum.Gen. article common variants in MSR1 Supplemental data for Nature Genetics article high risk variants in MSR1 Press release for Nature Genetics article Abstract of Nature Genetics article Departure from HWE as a screen for genotyping error: Supplemental Data for Human Genetics article! back to top Medical Center Departments Academic Computing Aegis Family Health Centers Aging Air Care Alliance for Health Alumni Affairs and Development Anesthesiology Arts Alive Biochemistry Bioethics Committee Biomedical Communications Bookstore Breathing Plus Brenner Children's Hospital Cancer Biology Cardiothoracic Surgery Center For Healthcare Research and Quality Center For Investigative Neuroscience Center For Network Computing (Telemedicine) Center For Voice Disorders Clinical Microbiology Laboratory Community Training Center Comparative Medicine Compliance Office: NCBH Compliance Office: WFU CompRehab Comprehensive Cancer Center CompuMed Continuing Education, Office of

9. Introduction To Genomics And Medical Genetics At Wake Forest University you are here home Directors' Welcome, Welcome to the website for The Centerfor human genomics at Wake Forest University School of Medicine. http://www.wfubmc.edu/docs/genomics/intro.htm

you are here: home Directors' Welcome Welcome to the website for The Center for Human Genomics at Wake Forest University School of Medicine. We hope to provide information and resources useful to visitors. The Center for Human Genomics was established in June 2000 as part of a new $67 million research initiative at the Wake Forest University School of Medicine. The Center is comprised of faculty members with expertise in a variety of disciplines, whose primary purpose is to investigate genetic mechanisms in the development and progression of complex human diseases. Our research priorities include cardiovascular disease diabetes prostate cancer , and pulmonary disease The aims of our Center are to: Identify genes that contribute to common human diseases Determine how these genes interact with environmental risk factors Define the context under which interventions can be devised to prevent disease Facilitate for the development of novel therapeutic regimes Investigate interactions between genes and therapeutic responses to drug therapy The structure of the Center for Human Genomics is designed for systematic, high-throughput genetic analysis. Using laboratories that are specialized for high-throughput genotyping, sequencing, and functional genomics, combined with an experienced analytical core, the Center has generated and analyzed considerable amounts of data that have lead to meaningful discoveries in each of its target areas.

10. Human Genomics Innovations And Patents human genomics Innovations and Patents © 2002, XQ23.COM Research More informationon human genomics and human genomics Research References. http://www.health.xq23.com/updates/Human_Genomics.html

Human Genomics Innovations and Patents © 2002, XQ23.COM Research Aerospace Medicine Agriculture Allergy Anatomy ... Great Minds LEGISLATION Arthritis Legislation More information on: Human Genomics and Human Genomics Research References. Recent U.S. patents related to Human Genomics: 6,348,314: Invasive cleavage of nucleic acids 6,300,485: Myosin IXa and cyclic nucleotide gated channel-15 (CNGC-15) polynucleotides, polypeptides, compositions, methods, and uses thereof 6,294,330: Protein fragment complementation assays for the detection of biological or drug interactions 6,270,964: Protein fragment complementation assays for the detection of biological or drug interactions 6,242,201: Identification of the P21WaF1-PCNA interaction site and therapeutic applications thereof 6,080,842: Human ATP binding-cassette transport protein 5,874,283: Mammalian flap-specific endonuclease 5,858,719: Polynucleotides encoding human ATP binding-cassette transport protein and methods of use 6,369,097: Treatment and prevention of hepatic disorders 6,369,080: Selective factor Xa inhibitors

11. Myriad Genetics - A Biopharmaceutical Company Providing Genetic Testing Services A biotechnology company focused on human genomics. http://www.myriad.com/

site archive site archive

12. HUMAN GENOMICS human genomics. THE BASIS OF THE MEDICINE OF TOMORROW. IFCC and entitled human genomics the Basis of the Medicine of Tomorrow . The http://www.leeds.ac.uk/ifcc/CD/roche/letter.html

HUMAN GENOMICS THE BASIS OF THE MEDICINE OF TOMORROW IFCC and Roche have established a series of Conferences entitled "Human Genomics: the Basis of the Medicine of Tomorrow". The purpose of this series of Conferences is to highlight progress in molecular genetics and its potential in diagnosis and therapy. It is intended to broadly cover the impact of genomics on modern medicine, including improved use of molecular diagnostic methods in clinical laboratories, quality assurance and ethical considerations of genetics technologies. Molecular biology techniques are expected to revolutionize drug discovery and management of treatment. Ultrasensitive molecular diagnotics, such as Polymerase Chain Reaction, will contribute to improving overall health care in medical and economic terms. The first Conference will focus on improved DNA diagnostics and define the role of the clinical chemistry laboratory in the future. The symposium entitled "Recent Progress in Molecular Biology Technology" is to be held in Singapore, 15 - 18 March 1998. We wish to bring together scientists specialized in the field of molecular diagnostics for discussion and preparation of recommendations for better clinical use of these new technolgies.

13. HUMAN GENOMICS human genomics. THE BASIS OF THE MEDICINE OF TOMORROW. Joint Conferenceof IFCC Roche Diagnostics. Raffles City Convention Centre http://www.leeds.ac.uk/ifcc/CD/roche/

HUMAN GENOMICS THE BASIS OF THE MEDICINE OF TOMORROW Joint Conference of IFCC - Roche Diagnostics 2 Stamford Road, Singapore 178882 Opening Key note speech Sunday evening 15 March 1998 The role of genomics in diagnostic and therapeutical medicine of the future Home Page Invitation Program Outline General Information ... Registration of Interest Form

14. Institute Of Biopharmaceutical Sciences Sciences Network New Research Areas Core technologies Research Programmes SynergyIBS and BSN PHG Programme for human genomics Dublin Molecular Medicine http://www.inst-biopharmsci.org/pages/phg/phg.html

Research Background Institute of Biopharmaceutical Sciences Core Technologies ... Genomics I B S Institute of Biopharmaceutical Sciences Core technologies Research projects ... Collaborating Institutions B S N Biopharmaceutical Sciences Network New Research Areas Core technologies ... Synergy -IBS and BSN P H G Programme for Human Genomics Dublin Molecular Medicine Centre ... Education Researchers Investigators and Collaborators Collaborator Publications Full Publication List What's New News from the IBS Details of Awards Appointments Articles Opportunities Employment with the IBS Lectureships Postdoctoral Positions Mass Spectrometry ... Other Positions General lnformation Further Information related to the IBS The Institute of Biopharmaceutical Sciences -The Programme for Human Genomics- A BSN - DMMC Collaboration IBS Intranet Site (local RCSI only) Click for Best Viewing Options Down the page: Dublin Molecular Medicine Centre Research Technology Bioresources ... Education The key ambition of the Programme is to establish Dublin as a major centre for human genomics. The landmark completion of the Human Genome Project provides a unique resource for biomedical sciences. There are two major limitations to harnessing the genetic information; one is identifying genes potentially involved in human disease and the second is the availability of patient populations in which to study these genes. The latter is a major problem, because if these populations are not planned now, the huge developments in high-throughput genotyping that will occur in the next 5 years cannot be successfully applied.

15. Institute Of Biopharmaceutical Sciences Sciences Core Technologies Research Projects Clinical Research Centre BiopharmaceuticalSciences Network Programme for human genomics IBS Institute of http://www.inst-biopharmsci.org/

Research Background Institute of Biopharmaceutical Sciences Core Technologies ... Human Genomics I B S Institute of Biopharmaceutical Sciences Core technologies Research projects ... Collaborating Institutions B S N Biopharmaceutical Sciences Network New Research Areas Core technologies ... Synergy -IBS and BSN P H G Programme for Human Genomics Dublin Molecular Medicine Centre ... Education Researchers Investigators and Collaborators Highlighted Publications Full Publication List What's New News from the IBS Details of Awards Appointments Articles Opportunities Employment with the IBS Lectureships Postdoctoral Positions Mass Spectrometry ... Other Positions General lnformation Further Information related to the IBS Welcome to the Institute of Biopharmaceutical Sciences (Link to RCSI website) IBS Intranet Site (local RCSI only) Click for Best Viewing Options The Institute of Biopharmaceutical Sciences (IBS) at The Royal College of Surgeons in Ireland (RCSI) Through further funding in HEA Cycles 2 and 3, the Institute has expanded its research programmes and formed collaborations, with major Irish Universities, to establish the Biopharmaceutical Sciences Network (BSN) and the Programme for Human Genomics (PHG) UCD UCC Trinity College and Maynooth to collaborate on research and share advanced facilities available at the RCSI Researchers have access to a number of core biotechnologies at the college, including

16. Liv4Evr.com - Predictive Human Genomics Click on the image of the book to learn more about it, or press theOrder button to purchase it. Predictive human genomics Is Here. http://liv4evr.com/news/predictive_genomics.php

Click on the image of the book to learn more about it, or press the Order button to purchase it. Predictive Human Genomics Is Here by Terry Grossman (article published on KurzweilAI.net on May 29th, 2002) Thanks to breakthroughs in genomics testing, physicians now have tools for true preventive medicine. Gene chips and genomics test panels can predict one’s predisposition towards many serious and often preventable genetic diseases and allow doctors to modify gene expression through precise, targeted, individualized interventions. The monumental accomplishment of decoding the human genome is nearly complete. The results of work of the official government-sponsored Human Genome Project together with the efforts of private firms such as Celera and Human Genome Sciences has created a true inflection point in the curve of medical history. The human genome, arguably The Rosetta Stone of the human body, is presently undergoing intense scrutiny by scientists in nearly every country in the world. The potential benefits of these efforts for improving human health and well-being are incalculable. "The greatest payoff from understanding the human genome is likely to be an illumination of the molecular pathogenesis of disorders that are currently poorly understood and for which treatments are frequently sub-optimal .Genomics offers the greatest opportunity for development of targeted therapy since the development of antibiotics,"

17. Gene(sis) Contemporary Art Explores Human Genomics Press Release Gene(sis) Contemporary Art Explores human genomics seeks to bridge art and sciencewhile showcasing powerful new artwork created in direct response to the http://www.henryart.org/press/prgenesis.htm

18. Past Exhibitions: Gene(sis) gene(sis) Contemporary Art Expolers human genomics Stroum / South Galleryand elsewhere April 5 Sugust 25, 2002. In 2000, The Human http://www.henryart.org/exhibits/past/past_genesis.htm

gene(sis) Contemporary Art Expolers Human Genomics Stroum / South Gallery and elsewhere April 5 - Sugust 25, 2002 In 2000, The Human Genome Project, a public consortium, and Celera Genomics, a private company, jointly announced the completion of a rough draft of the human genome, the molecular blueprint of a human being. Ever since, debates over DNA ownership and personal privacy, therapeutic and reproductive cloning, the future of science as a private venture or public endeavor and the introduction of new plant and animal life forms continue to dominate headlines. From digitally-altered photographs of "manimals" and artistic explorations of other transgenic beings, to DNA portraits and abstract "gene-mapping" paintings, Gene(sis): Contemporary Art Explores Human Genomics explores the potential social, emotional and ethical implications of one of the most compelling subjects of our times. Organized by the Henry Art Gallery and curated by Assistant Curator Robin Held, Gene(sis) is the most extensive exhibition to date to consider these issues from artistic perspectives. The exhibition functions as a catalyst for a robust schedule of public programs organized throughout the Puget Sound region by the Henry Art Gallery and its community partners.

19. UCL - School Of Public Policy - Publications - Human Genomics About SPP, SPP People, Teaching, Research, Publications, SPP Seminars, SPP Intranet,How To Find Us, You are here Home Publications - human genomics, Sun/16/03/2003. http://www.ucl.ac.uk/spp/publications/human_genomics.php

Home About SPP SPP People Teaching ... How To Find Us You are here: Home Publications Human Genomics Tue/18/03/2003 Human Genomics : Prospects for Health Care and Public Policy Author: Sir Mark Richmond Executive Summary Advances in genetics are already being applied on a substantial scale by the pharmaceutical industry to aid drug discovery and development. At present, provided that requirements with respect to informed consent and privacy of personal data are met, there are few impediments to using genetics for drug development, notably for the design and execution of clinical trials. Indeed this approach is becoming widespread in the pharmaceutical industry and is widely referred to as pharmacogenomics. In general, these programmes are well accepted by the public and considerable benefit is seen as likely to flow from them. Outside the industry, genetic tests to screen for inherited monogenic disorders in populations seen to be 'at risk' have been used for years and are well accepted. Indeed, in some jurisdictions, such tests are mandatory in certain cases. From the social and ethical point of view, screening for monogenic disorders is viewed as no different from screening for physiological characters. Genetic screening of broadly defined populations can provide much valuable information for governments and for the pharmaceutical, insurance and healthcare industries. For governments, it will provide predictive information that will aid in the planning of future healthcare provision. For the pharmaceutical and healthcare industries, it will provide information about the shape of future markets. For the insurance industry, it will give insight into the future health of the individuals.

20. National Health And Medical Research Council - Human Genomics: Australia's Inves NHMRC, Media Release. 4 May 2001, human genomics Australia’s investmentin ‘cuttingedge’ medicine. TODAY’S awarding of $8,276,000 http://www.health.gov.au/nhmrc/media/2001rel/genomics.htm

For text only browsers, click here to see full site index Media Release 4 May 2001 Professor Nicholas Martin (Queensland Institute of Medical Research): Linkage analysis for complex human traits in twin families - total funding of $1,000,000 over three years. Professor Ben Adler (Department of Microbiology, Monash University): Sequence and genome analysis of Leptospira species - total funding of $2,169,000 over three years; and Professor David Kemp (Queensland Institute for Medical Research): Gene discovery for the Scabes Mite Sarcoptes scabiei - total funding of $1,110,000 over three years. Media Contact: For more information or comment from Professor Warwick Anderson, contact Brett Heffernan on (02) 6289 5442, or 0411 255 236. ^ to top URL : http://www.nhmrc.gov.au/ media/2001rel/genomics.htm Privacy/ Security/ Electronic Transaction Produced by NHMRC Date created by NHMRC 04 May, 2001

Page 1     1-20 of 105    1  | 2  | 3  | 4  | 5  | 6  | Next 20